CBAY Stock Hits 2-Year Low On Disappointing Drug Data News
CBAY stock is under severe selling pressure after CymaBay Therapeutics Inc (NASDAQ:CBAY) reported interim data from an ongoing Phase 2b clinical trial for seladelpar. Setback for CymaBay California-based CymaBay Therapeutics has had a setback in ... [Read]
PRVB Stock Skyrockets As Investors Cheer Teplizumab’s Positive Results
PRVB stock in on fire and skyrockets as much as 300% after Provention Bio Inc (NASDAQ:PRVB) announced positive outcomes from its trial of teplizumab, its lead candidate. PRVB stock Jumps Big New Jersey-based Provention Bio, ... [Read]
Small-Cap Stocks to Watch: Innoviva and PetMed Express
The small-cap market is unearthing some shares at present that could return for investors in the not too distant future. The recent downturn has hit some stocks hard, but this isn’t something that should scare ... [Read]
PTI Stock Jumps As EU Grants Orphan Drug Designation
PTI stock is moving higher in Tuesday’s session following the news that Proteostasis Therapeutics Inc (NASDAQ:PTI) received orphan drug designation in the EU for PTI-428, its treatment for cystic fibrosis. Orphan Drug Designation Boston, Massachusetts-based ... [Read]
CARA Stock Skyrockets 20% After Positive Results On KORSUVA
CARA stock is on fire as Cara Therapeutics Inc (NASDAQ:CARA) reported positive topline results from a Phase 3 clinical trial, KALM-1, evaluating KORSUVA. Cara’s KORSUVA Successful As far as therapeutics companies are concerned, the completion ... [Read]
PBYI Stock Nosedives: Puma Biotechnology’s Nerlynx Revenue Falls
PBYI stock is the biggest loser in the biotech sector after Puma Biotechnology Inc. (NASDAQ:PBYI) reported disappointing revenue for its only commercial product, Nerlynx. Nevertheless, the company posted improved loss and revenue for the fiscal ... [Read]
BioTime Stock: “Buy” Ratings Abound, Should You Take Note?
BioTime stock is currently selling for $1.18 USD on the NYSE American exchange. At the time of writing, shares are down nearly 5%. Despite a rough few trading days, BTX stock has a consensus rating ... [Read]